Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C12H20NO8S.Ca |
| Molecular Weight | 716.786 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].[H][C@@]12CO[C@@]3(COS([NH-])(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2.[H][C@@]45CO[C@@]6(COS([NH-])(=O)=O)OC(C)(C)O[C@@]6([H])[C@]4([H])OC(C)(C)O5
InChI
InChIKey=VNRLRDKZOMPUAG-RZTSBURASA-N
InChI=1S/2C12H20NO8S.Ca/c2*1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12;/h2*7-9H,5-6H2,1-4H3,(H-,13,14,15);/q2*-1;+2/t2*7-,8-,9+,12+;/m11./s1
DescriptionSources: http://www.drugbank.ca/drugs/DB00273Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020505s055,020844s046lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00273
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020505s055,020844s046lbl.pdf
Topiramate is an anticonvulsant indicated in the treatment of epilepsy and migraine. Topiramate enhances GABA-activated chloride channels. In addition, topiramate inhibits excitatory neurotransmission, through actions on kainate and AMPA receptors. There is evidence that topiramate has a specific effect on GluR5 kainate receptors. It is also an inhibitor of carbonic anhydrase, particular subtypes II and IV, but this action is weak and unlikely to be related to its anticonvulsant actions, but may account for the bad taste and the development of renal stones seen during treatment. Its possible effect as a mood stabilizer seems to occur before anticonvulsant qualities at lower dosages. Topiramate inhibits maximal electroshock and pentylenetetrazol-induced seizures as well as partial and secundarily generalized tonic-clonic seizures in the kindling model, findings predective of a broad spectrum of antiseizure activities clinically. The precise mechanism of action of topiramate is not known. However, studies have shown that topiramate blocks the action potentials elicited repetitively by a sustained depolarization of the neurons in a time-dependent manner, suggesting a state-dependent sodium channel blocking action. Topiramate also augments the activity of the neurotransmitter gamma-aminobutyrate (GABA) at some subtypes of the GABAAreceptor (controls an integral chloride channel), indicating a possible mechanism through potentiation of the activity of GABA. Topiramate also demonstrates antagonism of the AMPA/kainate subtype of the glutamate excitatory amino acid receptor. It also inhibits carbonic anhydrase (particularly isozymes II and IV), but this action is weak and unlikely to be related to its anticonvulsant actions. Topiramate is used for the treatment and control of partial seizures and severe tonic-clonic (grand mal) seizures and also for the prevention of migraine headaches. In children it is also used for treatment of Lennox-Gastaut syndrome. Topiramate is sold under the brand name Topamax. A combination product containing phentermine and topiramate extended-release called QSYMIA® is indicated for the management of obesity.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL205 |
5.0 nM [Ki] | ||
Target ID: CHEMBL3729 |
4.9 µM [Ki] | ||
Target ID: CHEMBL2326 |
0.9 nM [Ki] | ||
Target ID: CHEMBL3242 |
3.8 nM [Ki] | ||
Target ID: CHEMBL1962 Sources: http://www.drugbank.ca/drugs/DB00273 |
|||
Target ID: CHEMBL4789 |
63.0 nM [Ki] | ||
Target ID: CHEMBL3969 |
30.0 nM [Ki] | ||
Target ID: CHEMBL3912 |
47.0 nM [Ki] | ||
Target ID: CHEMBL1845 Sources: http://www.drugbank.ca/drugs/DB00273 |
|||
Target ID: CHEMBL2109241 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | TOPAMAX Approved UseTOPAMAX is indicated for:
Monotherapy epilepsy: Initial monotherapy in patients > 2 years of age with partial onset or primary generalized tonic-clonic seizures
Adjunctive therapy epilepsy: Adjunctive therapy for adults and pediatric patients (2 to 16 years of age) with partial onset seizures or primary generalized tonic-clonic seizures, and in patients >2 years of age with
seizures associated with Lennox-Gastaut syndrome (LGS)
Migraine: Treatment for adults and adolescents 12 years of age and older for prophylaxis of migraine headache Launch Date1996 |
|||
| Preventing | TOPAMAX Approved UseTOPAMAX is indicated for:
Monotherapy epilepsy: Initial monotherapy in patients > 2 years of age with partial onset or primary generalized tonic-clonic seizures
Adjunctive therapy epilepsy: Adjunctive therapy for adults and pediatric patients (2 to 16 years of age) with partial onset seizures or primary generalized tonic-clonic seizures, and in patients >2 years of age with
seizures associated with Lennox-Gastaut syndrome (LGS)
Migraine: Treatment for adults and adolescents 12 years of age and older for prophylaxis of migraine headache Launch Date1996 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.98 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOPIRAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOPIRAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.46 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOPIRAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
1.63 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOPIRAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
18.38 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774 |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOPIRAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
28.73 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774 |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOPIRAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.68 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOPIRAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
350.3 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOPIRAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
311.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOPIRAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
57.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOPIRAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
59.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOPIRAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
23 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOPIRAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
18.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOPIRAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
22 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774 |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOPIRAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
20 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774 |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOPIRAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
23 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8930774 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOPIRAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
59% |
unknown, unknown |
TOPIRAMATE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1200 mg 1 times / day steady, oral MTD Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: |
healthy, 23.3 years (range: 20–26 years) n = 8 Health Status: healthy Age Group: 23.3 years (range: 20–26 years) Sex: M+F Population Size: 8 Sources: |
|
4000 mg single, oral Overdose |
unknown, 24 years n = 1 Health Status: unknown Age Group: 24 years Sex: F Population Size: 1 Sources: |
|
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 6-15 years n = 77 Health Status: unhealthy Condition: Epilepsy Age Group: 6-15 years Population Size: 77 Sources: |
Disc. AE: Attention concentration difficulty, Fever... AEs leading to discontinuation/dose reduction: Attention concentration difficulty (>=2) Sources: Fever (>=2) Flushing (>=2) Confusion (>=2) |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >16 years n = 159 Health Status: unhealthy Condition: Epilepsy Age Group: >16 years Population Size: 159 Sources: |
Disc. AE: Memory impairment, Fatigue... AEs leading to discontinuation/dose reduction: Memory impairment (>=2) Sources: Fatigue (>=2) Asthenia (>=2) Insomnia (>=2) Somnolence (>=2) Paresthesia (>=2) |
1400 mg 1 times / day steady, oral Highest studied dose Dose: 1400 mg, 1 times / day Route: oral Route: steady Dose: 1400 mg, 1 times / day Sources: |
unhealthy, adult (>16 years) n = 1757 Health Status: unhealthy Condition: epilepsy Age Group: adult (>16 years) Sex: M+F Population Size: 1757 Sources: |
Disc. AE: Psychomotor retardation, Memory impairment... AEs leading to discontinuation/dose reduction: Psychomotor retardation (4%) Sources: Memory impairment (3.2%) Fatigue (3.2%) Confusion (3.1%) Somnolence (3.2%) Attention concentration difficulty (2.9%) Anorexia (2.7%) Depression (2.6%) Dizziness (2.5%) Weight decrease (2.5%) Nervousness (2.3%) Ataxia (2.1%) Paresthesia (2%) |
30 mg/kg 1 times / day steady, oral Dose: 30 mg/kg, 1 times / day Route: oral Route: steady Dose: 30 mg/kg, 1 times / day Sources: |
unhealthy, pediatric (<16 years) n = 310 Health Status: unhealthy Condition: epilepsy Age Group: pediatric (<16 years) Population Size: 310 Sources: |
Disc. AE: Convulsions aggravated, Attention concentration difficulty... AEs leading to discontinuation/dose reduction: Convulsions aggravated (2.3%) Sources: Attention concentration difficulty (1.6%) Language disorder (1.3%) Personality disorder (1.3%) Somnolence (1.3%) |
96 g single, oral Overdose Dose: 96 g Route: oral Route: single Dose: 96 g Sources: |
unknown n = 1 Health Status: unknown Population Size: 1 Sources: |
Other AEs: Coma... Other AEs: Coma (1 patient) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Attention concentration difficulty | >=2 Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 6-15 years n = 77 Health Status: unhealthy Condition: Epilepsy Age Group: 6-15 years Population Size: 77 Sources: |
| Confusion | >=2 Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 6-15 years n = 77 Health Status: unhealthy Condition: Epilepsy Age Group: 6-15 years Population Size: 77 Sources: |
| Fever | >=2 Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 6-15 years n = 77 Health Status: unhealthy Condition: Epilepsy Age Group: 6-15 years Population Size: 77 Sources: |
| Flushing | >=2 Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 6-15 years n = 77 Health Status: unhealthy Condition: Epilepsy Age Group: 6-15 years Population Size: 77 Sources: |
| Asthenia | >=2 Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >16 years n = 159 Health Status: unhealthy Condition: Epilepsy Age Group: >16 years Population Size: 159 Sources: |
| Fatigue | >=2 Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >16 years n = 159 Health Status: unhealthy Condition: Epilepsy Age Group: >16 years Population Size: 159 Sources: |
| Insomnia | >=2 Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >16 years n = 159 Health Status: unhealthy Condition: Epilepsy Age Group: >16 years Population Size: 159 Sources: |
| Memory impairment | >=2 Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >16 years n = 159 Health Status: unhealthy Condition: Epilepsy Age Group: >16 years Population Size: 159 Sources: |
| Paresthesia | >=2 Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >16 years n = 159 Health Status: unhealthy Condition: Epilepsy Age Group: >16 years Population Size: 159 Sources: |
| Somnolence | >=2 Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >16 years n = 159 Health Status: unhealthy Condition: Epilepsy Age Group: >16 years Population Size: 159 Sources: |
| Paresthesia | 2% Disc. AE |
1400 mg 1 times / day steady, oral Highest studied dose Dose: 1400 mg, 1 times / day Route: oral Route: steady Dose: 1400 mg, 1 times / day Sources: |
unhealthy, adult (>16 years) n = 1757 Health Status: unhealthy Condition: epilepsy Age Group: adult (>16 years) Sex: M+F Population Size: 1757 Sources: |
| Ataxia | 2.1% Disc. AE |
1400 mg 1 times / day steady, oral Highest studied dose Dose: 1400 mg, 1 times / day Route: oral Route: steady Dose: 1400 mg, 1 times / day Sources: |
unhealthy, adult (>16 years) n = 1757 Health Status: unhealthy Condition: epilepsy Age Group: adult (>16 years) Sex: M+F Population Size: 1757 Sources: |
| Nervousness | 2.3% Disc. AE |
1400 mg 1 times / day steady, oral Highest studied dose Dose: 1400 mg, 1 times / day Route: oral Route: steady Dose: 1400 mg, 1 times / day Sources: |
unhealthy, adult (>16 years) n = 1757 Health Status: unhealthy Condition: epilepsy Age Group: adult (>16 years) Sex: M+F Population Size: 1757 Sources: |
| Dizziness | 2.5% Disc. AE |
1400 mg 1 times / day steady, oral Highest studied dose Dose: 1400 mg, 1 times / day Route: oral Route: steady Dose: 1400 mg, 1 times / day Sources: |
unhealthy, adult (>16 years) n = 1757 Health Status: unhealthy Condition: epilepsy Age Group: adult (>16 years) Sex: M+F Population Size: 1757 Sources: |
| Weight decrease | 2.5% Disc. AE |
1400 mg 1 times / day steady, oral Highest studied dose Dose: 1400 mg, 1 times / day Route: oral Route: steady Dose: 1400 mg, 1 times / day Sources: |
unhealthy, adult (>16 years) n = 1757 Health Status: unhealthy Condition: epilepsy Age Group: adult (>16 years) Sex: M+F Population Size: 1757 Sources: |
| Depression | 2.6% Disc. AE |
1400 mg 1 times / day steady, oral Highest studied dose Dose: 1400 mg, 1 times / day Route: oral Route: steady Dose: 1400 mg, 1 times / day Sources: |
unhealthy, adult (>16 years) n = 1757 Health Status: unhealthy Condition: epilepsy Age Group: adult (>16 years) Sex: M+F Population Size: 1757 Sources: |
| Anorexia | 2.7% Disc. AE |
1400 mg 1 times / day steady, oral Highest studied dose Dose: 1400 mg, 1 times / day Route: oral Route: steady Dose: 1400 mg, 1 times / day Sources: |
unhealthy, adult (>16 years) n = 1757 Health Status: unhealthy Condition: epilepsy Age Group: adult (>16 years) Sex: M+F Population Size: 1757 Sources: |
| Attention concentration difficulty | 2.9% Disc. AE |
1400 mg 1 times / day steady, oral Highest studied dose Dose: 1400 mg, 1 times / day Route: oral Route: steady Dose: 1400 mg, 1 times / day Sources: |
unhealthy, adult (>16 years) n = 1757 Health Status: unhealthy Condition: epilepsy Age Group: adult (>16 years) Sex: M+F Population Size: 1757 Sources: |
| Confusion | 3.1% Disc. AE |
1400 mg 1 times / day steady, oral Highest studied dose Dose: 1400 mg, 1 times / day Route: oral Route: steady Dose: 1400 mg, 1 times / day Sources: |
unhealthy, adult (>16 years) n = 1757 Health Status: unhealthy Condition: epilepsy Age Group: adult (>16 years) Sex: M+F Population Size: 1757 Sources: |
| Fatigue | 3.2% Disc. AE |
1400 mg 1 times / day steady, oral Highest studied dose Dose: 1400 mg, 1 times / day Route: oral Route: steady Dose: 1400 mg, 1 times / day Sources: |
unhealthy, adult (>16 years) n = 1757 Health Status: unhealthy Condition: epilepsy Age Group: adult (>16 years) Sex: M+F Population Size: 1757 Sources: |
| Memory impairment | 3.2% Disc. AE |
1400 mg 1 times / day steady, oral Highest studied dose Dose: 1400 mg, 1 times / day Route: oral Route: steady Dose: 1400 mg, 1 times / day Sources: |
unhealthy, adult (>16 years) n = 1757 Health Status: unhealthy Condition: epilepsy Age Group: adult (>16 years) Sex: M+F Population Size: 1757 Sources: |
| Somnolence | 3.2% Disc. AE |
1400 mg 1 times / day steady, oral Highest studied dose Dose: 1400 mg, 1 times / day Route: oral Route: steady Dose: 1400 mg, 1 times / day Sources: |
unhealthy, adult (>16 years) n = 1757 Health Status: unhealthy Condition: epilepsy Age Group: adult (>16 years) Sex: M+F Population Size: 1757 Sources: |
| Psychomotor retardation | 4% Disc. AE |
1400 mg 1 times / day steady, oral Highest studied dose Dose: 1400 mg, 1 times / day Route: oral Route: steady Dose: 1400 mg, 1 times / day Sources: |
unhealthy, adult (>16 years) n = 1757 Health Status: unhealthy Condition: epilepsy Age Group: adult (>16 years) Sex: M+F Population Size: 1757 Sources: |
| Language disorder | 1.3% Disc. AE |
30 mg/kg 1 times / day steady, oral Dose: 30 mg/kg, 1 times / day Route: oral Route: steady Dose: 30 mg/kg, 1 times / day Sources: |
unhealthy, pediatric (<16 years) n = 310 Health Status: unhealthy Condition: epilepsy Age Group: pediatric (<16 years) Population Size: 310 Sources: |
| Personality disorder | 1.3% Disc. AE |
30 mg/kg 1 times / day steady, oral Dose: 30 mg/kg, 1 times / day Route: oral Route: steady Dose: 30 mg/kg, 1 times / day Sources: |
unhealthy, pediatric (<16 years) n = 310 Health Status: unhealthy Condition: epilepsy Age Group: pediatric (<16 years) Population Size: 310 Sources: |
| Somnolence | 1.3% Disc. AE |
30 mg/kg 1 times / day steady, oral Dose: 30 mg/kg, 1 times / day Route: oral Route: steady Dose: 30 mg/kg, 1 times / day Sources: |
unhealthy, pediatric (<16 years) n = 310 Health Status: unhealthy Condition: epilepsy Age Group: pediatric (<16 years) Population Size: 310 Sources: |
| Attention concentration difficulty | 1.6% Disc. AE |
30 mg/kg 1 times / day steady, oral Dose: 30 mg/kg, 1 times / day Route: oral Route: steady Dose: 30 mg/kg, 1 times / day Sources: |
unhealthy, pediatric (<16 years) n = 310 Health Status: unhealthy Condition: epilepsy Age Group: pediatric (<16 years) Population Size: 310 Sources: |
| Convulsions aggravated | 2.3% Disc. AE |
30 mg/kg 1 times / day steady, oral Dose: 30 mg/kg, 1 times / day Route: oral Route: steady Dose: 30 mg/kg, 1 times / day Sources: |
unhealthy, pediatric (<16 years) n = 310 Health Status: unhealthy Condition: epilepsy Age Group: pediatric (<16 years) Population Size: 310 Sources: |
| Coma | 1 patient | 96 g single, oral Overdose Dose: 96 g Route: oral Route: single Dose: 96 g Sources: |
unknown n = 1 Health Status: unknown Population Size: 1 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of anti-epileptic drugs on glutamine synthetase activity in mouse brain. | 1999 Apr |
|
| Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. | 1999 Feb |
|
| Cerebral edema with herniation during acetaminophen-induced fulminant hepatic failure. | 2000 Jul |
|
| Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. | 2000 Jun |
|
| Comparative efficacy and tolerability of drug treatments for bipolar disorder. | 2001 |
|
| The management of refractory idiopathic epilepsies. | 2001 |
|
| Management strategies for refractory localization-related seizures. | 2001 |
|
| Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. | 2001 Apr |
|
| Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. | 2001 Apr |
|
| [Cognitive impairments due to add-on therapy with topiramate]. | 2001 Apr |
|
| Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action? | 2001 Apr |
|
| Topiramate in the treatment of acute mania. | 2001 Apr |
|
| Topiramate titration and tolerability. | 2001 Feb |
|
| Topiramate for bulimia nervosa in epilepsy. | 2001 Feb |
|
| Evaluating the tolerability of the newer mood stabilizers. | 2001 Jan |
|
| Advances in the treatment of epilepsy. | 2001 Jul 1 |
|
| Incoercible topiramate-related vomiting in a patient with epilepsy and mental retardation. | 2001 Jun |
|
| Topiramate abuse in a bipolar patient with an eating disorder. | 2001 Jun |
|
| Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. | 2001 Jun |
|
| The Stanley Foundation Bipolar Network. 2. Preliminary summary of demographics, course of illness and response to novel treatments. | 2001 Jun |
|
| A pilot study of topiramate as monotherapy in the treatment of acute mania. | 2001 Jun |
|
| Control of Tourette's syndrome with topiramate. | 2001 Jun |
|
| Topiramate for clozapine-induced seizures. | 2001 Jun |
|
| [Course of drug-resistant childhood epilepsy treated with topiramate]. | 2001 Mar 1-15 |
|
| Bilateral angle-closure glaucoma and ciliary body swelling from topiramate. | 2001 Nov |
|
| Re: Weight change with antipsychotic use. | 2001 Sep |
|
| Postmarketing experience with topiramate and cognition. | 2001 Sep |
Sample Use Guides
Recommended dose: 400 mg orally per day in 2 divided doses of 200 mg each
The dose should be achieved by titration:
Week 1: 25 mg orally in the morning and 25 mg orally in the evening
Week 2: 50 mg orally in the morning and 50 mg orally in the evening
Week 3: 75 mg orally in the morning and 75 mg orally in the evening
Week 4: 100 mg orally in the morning and 100 mg orally in the evening
Week 5: 150 mg orally in the morning and 150 mg orally in the evening
Week 6: 200 mg orally in the morning and 200 mg orally in the evening
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DBSALT002319
Created by
admin on Sat Dec 16 08:09:32 GMT 2023 , Edited by admin on Sat Dec 16 08:09:32 GMT 2023
|
PRIMARY | |||
|
P956SY6RA6
Created by
admin on Sat Dec 16 08:09:32 GMT 2023 , Edited by admin on Sat Dec 16 08:09:32 GMT 2023
|
PRIMARY | |||
|
72942003
Created by
admin on Sat Dec 16 08:09:32 GMT 2023 , Edited by admin on Sat Dec 16 08:09:32 GMT 2023
|
PRIMARY | |||
|
1246279-00-4
Created by
admin on Sat Dec 16 08:09:32 GMT 2023 , Edited by admin on Sat Dec 16 08:09:32 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
